ISRCTN30090285已完成1 期
A Phase Ib and randomised Phase II trial of pazopanib with or without fosbretabulin in advanced recurrent ovarian cancer
The Christie NHS Foundation Trust (UK)0 个研究点目标入组 33 人开始时间: 2014年4月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
研究概览
简要总结
2018 conference abstract in: https://doi.org/10.1093/annonc/mdy285.164
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Advanced, progressive, recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, which has recurred following at least one platinum-containing regimen.
- •2. Progressive disease according to RECIST 1.1 or GCIG criteria within 312 months of completing platinum-containing therapy, although this need not be the immediately preceding regimen.
- •3. World Health Organisation (WHO) performance status of 0 or 1 (Appendix 1).
- •4. Measurable disease (RECIST 1.1 (Appendix 2) or PD according to CA125 GCIG criteria with non-measurable disease on CT scan.
- •5. Life expectancy of at least 12 weeks.
- •6. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week (Day 7 to Day 1) before the patient receives the first dose of IMP. Laboratory Test Value required:
- •6.1. Haemoglobin (Hb) = 90 g/L
- •6.2. Absolute neutrophil count = 1.5 x 10*9/L
- •6.3. Platelet count = 100 x 10*9/L
- •6.4. Serum potassium within normal range
- •6.5. Bilirubin up to 1.5 x ULN and
- •6.6. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) = 2.5 x ULN unless raised due to hepatic metastatic disease in which case up to 5 x ULN is permissible
- •6.7. Calculated creatinine clearance or isotope clearance measurement = 40 mL/min
- •6.8. Activated partial thromboplastin time (aPTT) = 1.2 x ULN
- •6.9. Prothrombin Time (PT) or international normalised ratio (INR) = 1.3 x ULN
- •7. Urine protein dipstick of less than 2+, or if 2+ or greater the patient must have a 24-hour urinary protein value of less than 2 g.
- •8. Clinically euthyroid
- •9. Aged 18 years or over at the time of consent
- •10. Written (signed and dated) informed consent and capable of cooperating with treatment and follow-up
- •11. Patients can have received bevacizumab prior to trial entry providing that the last dose was administered at least 6 months before the first dose of IMP
- •Target Gender: Female ; Lower Age Limit 18 years
排除标准
- •1. Radiotherapy, surgery or tumour embolisation within 28 days before the first dose of IMP
- •2. Endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin C and six weeks for investigational medicinal products) before the first dose of IMP.
- •3. Ongoing grade = 2 toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Chief and Principal Investigators should not exclude the patient; and grade 1 or 2 neurotoxicity considered to be due to paclitaxel.
- •4. Female patients who are able to become pregnant (or are already pregnant or lactating). Those who have a negative serum or urine pregnancy test before enrolment and agree to use two highly effective forms of contraception (oral, injected or implanted hormonal contraception and condom, have an intrauterine device and condom, diaphragm with spermicidal gel and condom) for four weeks before entering the trial, during the trial and for six months afterwards are considered eligible.
- •5. Major thoracic or abdominal surgery from which the patient has not yet recovered.
- •6. At high medical risk because of non-malignant systemic disease including active uncontrolled infection.
- •7. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
- •8. History of any of the following cardiovascular conditions within the last six months:
- •8.1. Coronary revascularisation (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG])
- •8.2. Acute coronary syndrome (myocardial infarction [MI], unstable angina)
- •8.3. Symptomatic peripheral vascular disease
- •8.4. Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) (Appendix 4)
- •9. Patients who have sustained hypertension, defined as a systolic blood pressure (SBP) of > 140 mmHg or diastolic blood pressure (DBP) of > 90 mmHg, on three occasions.
- •10. ECG with evidence of clinically significant abnormalities.
- •11. Patients with a QTc > 480 ms or taking any drug known to prolong the QTc interval that cannot be stopped for the duration of the trial (Appendix 4).
- •12. Patients with pathologic bradycardia (<60 b/m in nonathletes), heart block (excluding first-degree block, being PR interval prolongation only).
- •13. History of cerebrovascular accident (including transient ischaemic attack [TIA]), pulmonary embolism or untreated deep vein thrombosis (DVT) within the past six months. Patients with recent DVT who have been treated with therapeutic anticoagulant agents for at least six weeks will be eligible, provided their INR (if taking oral anticoagulants) has been stable for this period of time.
- •14. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic and have had no requirement for steroids or anticonvulsant medication for six months prior to the first dose of IMP.
- •15. Clinically significant abnormalities that may increase the risk of gastrointestinal bleeding or perforation, including but not limited to:
研究者
相似试验
招募中
不适用
FASE II ONDERZOEK NAAR DEEFFECTIVITEIT VAN PAZOPANIB BIJ PATIËNTEN MET BAARMOEDERKANKER.Metastatic or locally advanced endometrial cancer not amenable to other therapyNL-OMON26478niversity Medical Center55
已完成
2 期
Pazopanib versus pacLitaxel in relapsed Urothelial TumOursCancerISRCTN73030316HS Greater Glasgow and Clyde (UK)131
已完成
2 期
An open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.endometrial canceruterine corpus carcinoma10046828NL-OMON39290Academisch Medisch Centrum55
进行中（未招募）
1 期
A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER] - PANTHER (version 6, 23 March 2012)EUCTR2009-016675-29-GBQueen Mary university of London104
已完成
2 期
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular DegenerationMacular DegenerationNCT01134055GlaxoSmithKline510